Pain Therapeutics, Inc. (PTIE) Declines to All-Time Low at $2.14 on Jun, 29

June 29, 2018 - By Sergio Grout

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

PTIE reached $2.14 during the last trading session after $0.12 change.Pain Therapeutics, Inc. is uptrending after having risen 133.72% since June 29, 2017. PTIE has 274,326 volume or 132.03% up from normal. The stock outperformed the S&P 500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news announced recently go to:,,, or The titles are as follows: “42 Biggest Movers From Yesterday” announced on June 28, 2018, “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” on June 27, 2018, “23 Stocks Moving In Wednesday’s Pre-Market Session” with a publish date: June 27, 2018, “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” and the last “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” with publication date: June 26, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is worth $14.76 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Last it reported negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: